Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	176.37M
Revenue (ttm)	13.93M
Net Income (ttm)	-39.71M
Shares Out	5.53M
EPS (ttm)	-8.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,362
Average Volume	6,197
Open	32.70
Previous Close	31.90
Day's Range	31.60 - 32.70
52-Week Range	31.20 - 84.00
Beta	0.70
RSI	45.89
Earnings Date	Sep 5, 2025

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 105
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2023, WSE:CTX's revenue was 13.20 million, an increase of 44.15% compared to the previous year's 9.16 million. Losses were -70.58 million, 96.6% more than in 2022.